These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 22374518)

  • 1. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
    Chang J; Sui M; Fan W
    Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
    Sui M; Jiang D; Hinsch C; Fan W
    Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death.
    Sui M; Huang Y; Park BH; Davidson NE; Fan W
    Cancer Res; 2007 Jun; 67(11):5337-44. PubMed ID: 17545614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells.
    Jiang Z; Guo J; Shen J; Jin M; Xie S; Wang L
    J Exp Clin Cancer Res; 2012 May; 31(1):42. PubMed ID: 22553917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
    O'Regan RM; Osipo C; Ariazi E; Lee ES; Meeke K; Morris C; Bertucci A; Sarker MA; Grigg R; Jordan VC
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2255-63. PubMed ID: 16609042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fulvestrant, a selective estrogen receptor down-regulator, sensitizes estrogen receptor negative breast tumors to chemotherapy.
    Jiang D; Huang Y; Han N; Xu M; Xu L; Zhou L; Wang S; Fan W
    Cancer Lett; 2014 May; 346(2):292-9. PubMed ID: 24462822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer.
    Tokuda E; Seino Y; Arakawa A; Saito M; Kasumi F; Hayashi S; Yamaguchi Y
    Breast Cancer Res Treat; 2012 Jun; 133(2):427-36. PubMed ID: 21909982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
    Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
    Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels.
    Yoneya T; Tsunenari T; Taniguchi K; Kanbe Y; Morikawa K; Yamada-Okabe H; Lee YH; Lee MH; Kwon LS
    Oncol Rep; 2009 Mar; 21(3):747-55. PubMed ID: 19212635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
    Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
    Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.
    Tabuchi Y; Matsuoka J; Gunduz M; Imada T; Ono R; Ito M; Motoki T; Yamatsuji T; Shirakawa Y; Takaoka M; Haisa M; Tanaka N; Kurebayashi J; Jordan VC; Naomoto Y
    Int J Oncol; 2009 Feb; 34(2):313-9. PubMed ID: 19148464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment.
    Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V
    J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isobavachalcone sensitizes cells to E2-induced paclitaxel resistance by down-regulating CD44 expression in ER+ breast cancer cells.
    Shi J; Chen Y; Chen W; Tang C; Zhang H; Chen Y; Yang X; Xu Z; Wei J; Chen J
    J Cell Mol Med; 2018 Nov; 22(11):5220-5230. PubMed ID: 30179299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenic trioxide re-sensitizes ERα-negative breast cancer cells to endocrine therapy by restoring ERα expression in vitro and in vivo.
    Zhang W; Wang L; Fan Q; Wu X; Wang F; Wang R; Ma Z; Yang J; Lu SH
    Oncol Rep; 2011 Sep; 26(3):621-8. PubMed ID: 21687957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of estrogen receptors alpha and beta in human breast carcinoma by exogenous leptin in nude mouse xenograft model.
    Yu W; Gu JC; Liu JZ; Wang SH; Wang Y; Zhang ZT; Ma XM; Song MM
    Chin Med J (Engl); 2010 Feb; 123(3):337-43. PubMed ID: 20193256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes.
    Moggs JG; Murphy TC; Lim FL; Moore DJ; Stuckey R; Antrobus K; Kimber I; Orphanides G
    J Mol Endocrinol; 2005 Apr; 34(2):535-51. PubMed ID: 15821115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
    Nukatsuka M; Saito H; Nakagawa F; Abe M; Uchida J; Shibata J; Matsuo K; Noguchi S; Kiniwa M
    Breast Cancer Res Treat; 2011 Jul; 128(2):381-90. PubMed ID: 20809360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.
    Bayliss J; Hilger A; Vishnu P; Diehl K; El-Ashry D
    Clin Cancer Res; 2007 Dec; 13(23):7029-36. PubMed ID: 18056179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VP-128, a novel oestradiol-platinum(II) hybrid with selective anti-tumour activity towards hormone-dependent breast cancer cells in vivo.
    Van Themsche C; Parent S; Leblanc V; Descôteaux C; Simard AM; Bérubé G; Asselin E
    Endocr Relat Cancer; 2009 Dec; 16(4):1185-95. PubMed ID: 19661132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.